Ranosidenib clinical trials
Also written HMPL-306.
How each study uses ranosidenib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the ranosidenib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- HMPL-306
- 4
Studies by the year they started
5 studies that test it; most in 2021 (2)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2021 | 2 |
| 2024 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test ranosidenib.
- Dec 2026Phase I Study of HMPL-306 for the Treatment of Gliomas With IDH1 and/or IDH2 MutationsPhase 1 · Hutchmed
Studies
Open first, then newest update. How each study uses ranosidenib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid LeukemiaRecruitingPhase 3HutchmedNCT06387069Written as HMPL-306 Regimen
- Phase I Study of HMPL-306 for the Treatment of Gliomas With IDH1 and/or IDH2 MutationsRecruitingPhase 1HutchmedNCT07025018Written as HMPL-306
- A Study of HMPL-306 in Advanced Solid Tumors With IDH MutationsTerminatedPhase 1HutchmedNCT04762602Written as HMPL-306
- A Study of HMPL-306 in Advanced Hematological Malignancies With mIDHTerminatedPhase 1HutchmedNCT04764474Written as HMPL-306
- A Study of HMPL-306 in Patients With IDH1 and/or IDH2 Mutation of Relapsed/Refractory Myeloid Leukemia/NeoplasmsStatus unknownPhase 1Hutchison Medipharma LimitedNCT04272957Written as HMPL-306
Codes
What other systems call ranosidenib · ClinicalTrials.gg INT017569
- UNII (FDA) PC64OXS2C2RANOSIDENIBOne source FDA
- NCI Thesaurus C175602RanosidenibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | PC64OXS2C2 | RANOSIDENIB | One source FDA |
| NCI Thesaurus | C175602 | Ranosidenib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.